If you are looking for our next president to lower your health care costs, there are multiple reasons to support President Biden over Donald Trump. One is insulin. Though Trump would like you to think otherwise, Juliette Cubanski and Tricia Neuman explain in a KFF report that Donald Trump did far less to contain the cost of insulin than President Biden.
To be clear, both President Biden and Donald Trump have lowered the cost of insulin for people with Medicare and for no other cohort of the population. But, access to lower-cost insulin for people with Medicare is far greater under President Biden than it was under President Trump.
Under President Biden, all 6,000 Medicare Part D prescription drug plans are required to keep the insulin copay at no more than $35 a month. President Trump did not require the Part D plans to charge a copay of no more than $35 a month; he made it voluntary. So, only 38 percent of Part D plans participated when he was president.
As a result, the Trump administration only helped 800,000 people with Medicare needing insulin. The Biden Administration is helping all 3.3 million people with Medicare needing insulin.
Under President Biden, all insulin products are covered. Donald Trump only required a subset of insulin products to be covered–one of each dosage form (vial, pen) and insulin type (rapid-acting, short-acting, intermediate-acting, and long-acting).
Under President Biden, the insulin cap applies to drugs under Medicare Part D and Part B. The Trump administration only applied the cap to Medicare Part D and not to insulin drugs administered by a physician under Part B.
President Biden is now proposing to ensure that everyone with commercial insurance also enjoys the $35 a month out-of-pocket cap on insulin. In fact, President Biden’s proposal was in the Inflation Reduction Act, but the Republicans took it out before it passed. And, Republicans in Congress want to repeal the Inflation Reduction Act, which would end the $35 out-of-pocket insulin cap, though Trump has not yet commented on this.
N.B. Rachel Cohrs Zhang reports for Stat that the idea for the $35 insulin cap came from Eli Lilly. The cap likely helps Lilly’s profits since it boosts insulin sales significantly, as more people can afford it. The cap doesn’t affect the price of the drug. So, everyone with Medicare ends up absorbing insulin’s lower out-of-pocket cost through higher premiums.
Here’s more from Just Care: